Clinical Trial Update: Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging study evaluating pradefovir in patients with compensated chronic hepatitis B has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Pradefovir (pradefovir)

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Hepatitis B, Chronic | Phase 2 | Status: COMPLETED